International Biotechnology Trust’s Ligand Pharmaceuticals LGND Stock Holding History

International Biotechnology Trust’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,702	Closed	-$833K	–	61
2019 Q2	$833K	Hold	11,702	–	–	0.31%	55
2019 Q1	$918K	Sell	11,702 -78,547	-87%	-$5.95M	0.34%	55
2018 Q4	$6M	Buy	90,249 +34,144	+61%	+$3.64M	3.72%	10
2018 Q3	$7.36M	Hold	56,105	–	–	3.5%	10
2018 Q2	$7.25M	Sell	56,105 -11,221	-17%	-$1.25M	2.78%	14
2018 Q1	$6.94M	Buy	67,326 +20,839	+45%	+$2.06M	2.71%	15
2017 Q4	$3.97M	Hold	46,487	–	–	1.4%	24
2017 Q3	$3.95M	Buy	46,487 +32,060	+222%	+$2.54M	1.54%	23
2017 Q2	$1.09M	Hold	14,427	–	–	0.42%	48
2017 Q1	$952K	Sell	14,427 -33,663	-70%	-$2.21M	0.36%	53
2016 Q4	$3.05M	Buy	+48,090	New	+$3.03M	1.37%	19

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

International Biotechnology Trust's LGND Position: Q3 2019 in Review

International Biotechnology Trust sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 11,702 shares — an estimated $833K sold.

International Biotechnology Trust first reported a position in LGND in Q4 2016 and held it in 11 quarters. The position peaked at $7.36M in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

International Biotechnology Trust reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
International Biotechnology Trust sold 11,702 Ligand Pharmaceuticals shares in Q3 2019, an estimated $833K.
International Biotechnology Trust first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 11 quarters.
International Biotechnology Trust's Ligand Pharmaceuticals position peaked at $7.36M in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on International Biotechnology Trust's 13F filing for Q3 2019, filed 14 Nov 2019.